The Canadian IC device market is a uniquely challenging space characterized by eroding ASPs, an aging population, and an increasing prevalence of complex lesions requiring use of niche devices, such as intravascular imaging catheters and CTO devices.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for IC devices in Canada across a 10-year period.
Shrinking health care budgets, adoption of tender contracts, and increasing competition will have a significantly impact pricing dynamics in Canada.
What market segments will be the most affected by strong price competition?
How have tender contracts affected market shares in the Canadian IC device market?
How will adoption of premium-priced devices affect ASP declines?
Markets for niche and novel products such as IVUS, FFR, OCT, and premium accessory devices present significant opportunities and will grow the fastest.
To what degree will these devices be adopted given the budget-conscious nature of Canadian facilities and the additional cost associated with their use?
Which market segments have the most potential for growth, and why?
Which segments will attract new competitors?
Highly anticipated BVS and DCBs have finally launched in Canada.
How will the launch of alternatives to metallic coronary stents affect the market?
Will DES penetration rates be diminished by these new technologies?
Will the introduction of DCBs alter the percentage of PCIs that are stented?
- Interventional Cardiology Devices - Market Insights - Canada
Author(s): Sangeetha Iyer, Pharm.D
Sangeetha Iyer is an analyst within the Cardiovascular Medtech Insights team at Decision Resource Group, specializing in structural heart closure and vascular access device markerts across the Asia Pacific region, as well as medical device pricing and regulations in China and Japan. Sangeetha has represnted India at the European Society of Cardiology confrerence in Greece(2016) and Sweden(2017), where her research poster was awarded the top prize. Sangeetha holds a Doctor of Pharmacy degree from the Manipal Academy of Higher Education. Follow Sangeetha on twitter: @Slyer_DRG